FC
CPRX

FORA Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

FORA Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,308
Closed -$226K – 536
2025
Q1 		$226K Buy
+9,308
New +$210K 0.02% 435
2024
Q4 		– Sell
-25,933
Closed -$516K – 423
2024
Q3 		$516K Buy
+25,933
New +$481K 0.06% 280

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FORA Capital's CPRX Position: Q2 2025 in Review

FORA Capital sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 9,308 shares — an estimated $226K sold.

FORA Capital first reported a position in CPRX in Q3 2024 and held it in 2 quarters. The position peaked at $516K in Q3 2024. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

  • FORA Capital reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • FORA Capital sold 9,308 Catalyst Pharmaceutical shares in Q2 2025, an estimated $226K.
  • FORA Capital first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 2 quarters.
  • FORA Capital's Catalyst Pharmaceutical position peaked at $516K in Q3 2024.
  • 365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on FORA Capital's 13F filing for Q2 2025, filed 13 Aug 2025.